China’s large and still growing population, accompanied by rising household wealth and rapid increases in healthcare spending, has transformed China into the world’s second-largest pharmaceutical market. In 2015, overall pharmaceutical sales in mainland China totaled more than $115 billion, placing China behind only the United States ($330 billion). With a population of over 1.3 billion, the sheer size of the market all but guarantees that the Chinese market will continue to grow despite the problems faced by the healthcare system. “Healthcare is the one market where the market size equals the population,” says Kent Kedl.
The week that was: Government eases regulation on foreign investment in China’s healthcare sector; Alibaba picks up a 10.35% stake in Singapore Post; and the government’s pricing and corruption crackdown squeezes profits of pharmaceutical companies in China. Mending China’s Healthcare System China’s healthcare system is in urgent need of an overhaul (for a detailed […]
China’s public healthcare system is ill-equipped to handle growing demand. On the other hand, private healthcare in China is not an easy field to play in due to several reasons. Will investment sentiment survive in the country’s beleaguered healthcare sector? It’s a typical scene in Subei People’s Hospital in Yangzhou, a third-tier city in China’s coastal […]